Literature DB >> 23969404

Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.

Masaomi Ikeda1, Tetsuo Fujita, Yasuyuki Amoh, Sumiyuki Mii, Kazumasa Matsumoto, Masatsugu Iwamura.   

Abstract

Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent. Skin toxicity, such as hand-foot skin reaction, is one of the frequent adverse effects of sorafenib. On the other hand, sorafenib-induced erythema multiforme is very rare, and Stevens-Johnson syndrome and toxic epidermal necrolysis induced by sorafenib have not been reported. We report the first case of Stevens-Johnson syndrome caused by sorafenib for metastatic renal cell carcinoma.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23969404     DOI： 10.1159/000351918

Source DB:  PubMed          Journal:  Urol Int        ISSN： 0042-1138            Impact factor:   2.089


  6 in total

1.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 2.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

3.  Sorafenib-associated facial acneiform eruption.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-12-25

Review 4.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

Review 5.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

6.  Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management.

Authors:  Yan Lin; Ping-Yu Liu
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.